AzTrials
AzTrials

Periodontal DiseasesNCT06075680

Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases

A study testing Non-Surgical Periodontal Treatment in people with Periodontal Diseases and Gingivitis, run by Marmara University at 1 site in Turkey (Türkiye).

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary IL-1beta, IL-18, NLRP3, ASC and Caspase-1 levels in gingivitis and Stage III Grade C periodontitis. 15 periodontally healthy, 15 gingivitis and 15 Stage III Grade C periodontitis patients were enrolled. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Diseases, Gingivitis, Periodontitis
What is being tested?
Non-Surgical Periodontal Treatment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteTurkey (Türkiye)
Study dates
4 Mar 2022to Nov 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • systemically healthy and non-smoker individuals
  • having ≥20 teeth present (except third molars)
  • individuals with periodontally healthy, gingivitis or stage III grade C periodontitis diagnoses

Who cannot join

  • having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
  • usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
  • periodontal treatment within the preceding 6 months.
  • pregnant/ lactating/ postmenopausal females.
  • Current orthodontic treatment.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Marmara University

    Istanbul, Maltepe, 34854

Other trials in Turkey (Türkiye)

About this study

Official title: Effect of Non-Surgical Periodontal Treatment on Inflammasome-Related Proteins in Periodontal Diseases

The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary IL-1beta, IL-18, NLRP3, ASC and Caspase-1 levels in gingivitis and Stage III Grade C periodontitis. 15 periodontally healthy, 15 gingivitis and 15 Stage III Grade C periodontitis patients were enrolled. At baseline, serum and saliva samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis and gingivitis patients received non-surgical periodontal treatment. Clinical parameters were re-measured and samples were re-collected at 1 and 3 months after treatment. Serum and salivary protein levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.

Read the detailed description

New insights into the first line of immune response to infection and stress signals at the cellular level have reported the participation of cytoplasmic nucleotide-binding domain-like receptors containing multi-protein complexes named inflammasomes. The inflammasomes play a key role in innate immunity by regulating maturation of proinflammatory cytokines of the interleukin 1beta and 18. The inflammasome depends on assembly of a sensor, for instance nod-like receptor family pyrin domaincontaining protein (NLRP), with an adaptor,apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), allowing recruitment and activation of an inflammatory caspase-1. Although different inflammasomes have been described, the NLRP3/ASC/caspase-1 multi-protein complex, known as NLRP3 inflammasome, has been most intensively studied.

Sample size was calculated based on a previous study concerning levels of inflammasome complex proteins in periodontal diseases.To maintain estimates at an optimal level of precision,minimize impact of exclusions and dropouts, and establish significant differences in results at a 95% confidence level, alfa value=0.05, and 83% power.Therefore, the study sample included a total of 45 patients( 15 periodontally healthy, 15 gingivitis, 15 sStage III Grade C Periodontitis). The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. Periodontal status of each patient was evaluated by a single calibrated periodontists with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=15) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10% in the whole mouth. Healthy group also exhibited no history of periodontitis. Gingivitis patients had PD≤3 mm, intact periodontium, no destruction in alveolar bone radiographically and BOP>10%. Stage III grade C patient had clinical attachment loss (CAL)≥ 5, radiographic bone loss (RBL) extending to the middle third of root and beyond, ≤ 4 tooth loss due to periodontitis, percentage of bone loss by age is >1.

Treatment The recruited periodontitis and gingivitis patients received conventional quadrant scaling and root planning (SRP). SRP was performed by the same clinician using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the SRP. No periodontal intervention was carried out in the periodontally healthy controls.

Saliva and Serum Sampling A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 am. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright and saliva was collected over a period of 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. The saliva samples were centrifuged at 5000 rpm for 10 minutes at room temperature, and supernatants were collected and stored at -80°C. A total of 5 mL of blood was collected from the antecubital fossa by venepuncture method. Serum was isolated from the blood by centrifuging at 3000 rpm for 20 minutes followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C.

Biomarker Immunoassays: Serum and salivary samples of IL-1beta, IL-18, NLRP3, ASC and Caspase-1 were measured by ELISA using commercial kits.

Statistical Analysis All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally disturbed, Friedman test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 1 month and 3 months after treatment. For inter-group comparisons, Mann-Whitney U test for normally and non-normally disturbed data. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each others in diseased group before and after treatment. All tests were performed at significance level of P <0.05.

Being tested
Non-Surgical Periodontal Treatment
Keywords
Periodontitis, Inflammasomes, Gingivitis
Medical subject headings
Periodontal Diseases, Gingivitis, Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non-Surgical Periodontal TreatmentProcedure or surgery

    The primary goal of nonsurgical periodontal therapy is to control microbial periodontal infection by removing bacterial biofilm, calculus, and toxins from periodontally involved root surfaces. Performing a thorough periodontal debridement under local anesthesia will stop disease progression and result in improvement in the clinical signs and symptoms of active disease

Study groups in NCT06075680
Study groupRoleWhat they receive
HealthyNo interventionPeriodontally healthy patients received no intervention.
GingivitisActive comparatorGingivitis group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The entire non-surgical periodontal treatment of gingivitis groups was completed in a total of 2 sessions in a week.
Receives: Procedure: Non-Surgical Periodontal Treatment
Stage III Grade C PeriodontitisActive comparatorStage III Grade C group received Non-Surgical Periodontal Treatment. They received Scaling and Root Planning procedure with ultrasonic scalers and hand curettes. The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Receives: Procedure: Non-Surgical Periodontal Treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Salivary NLRP3 levels (ng/ml)

    change in salivary NLRP3 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  2. Salivary ASC levels (pg/ml)

    change in salivary ASC levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  3. Salivary Caspase-1 levels (ng/ml)

    change in salivary Caspase-1 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  4. Salivary IL-1beta levels (pg/ml)

    change in salivary IL-1beta levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  5. Salivary IL-18 levels (pg/ml)

    change in salivary IL-18 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

Secondary outcomes (5)
  1. Serum NLRP3 levels (ng/ml)

    change in serum NLRP3 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  2. Serum ASC levels (pg/ml)

    change in serum ASC levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  3. Serum Caspase-1 levels (ng/ml)

    change in serum Caspase-1 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  4. Serum IL-1beta levels (pg/ml)

    change in serum IL-1beta levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

  5. Serum IL-18 levels (pg/ml)

    change in serum IL-18 levels from baseline to 1 month and 3 months after treatment

    Measured: from baseline to 1 month and 3 months after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2023
  2. Study start4 Mar 2022
  3. Primary completionNov 2023 (estimated)
  4. Study completionNov 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06075680
Sponsor's protocol ID
TDK-2022-10763
Status last verified
Oct 2023
First submitted
4 Oct 2023
Last updated
10 Oct 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Non-Surgical Periodontal Treatment in people with Periodontal Diseases and Gingivitis, run by Marmara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Salivary NLRP3 levels (ng/ml) (time frame: from baseline to 1 month and 3 months after treatment). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in